vs
Andersons, Inc.（ANDE）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Andersons, Inc.的1.6倍（$540.7M vs $329.5M），Andersons, Inc.净利率更高（20.5% vs -2.9%，领先23.4%），Andersons, Inc.同比增速更快（-2.4% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-77.1M），过去两年Andersons, Inc.的营收复合增速更高（-1.8% vs -2.3%）
安德森公司（The Andersons, Inc.）是1947年成立的美国农业企业，总部位于俄亥俄州莫米。公司起源于1940年代服务粮食行业的安德森货运站，是深耕农业领域的多元化企业，业务覆盖大宗商品贸易、可再生能源以及植物营养板块。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ANDE vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.6倍
$329.5M
营收增速更快
ANDE
高出11.8%
-14.1%
净利率更高
ANDE
高出23.4%
-2.9%
自由现金流更多
ICUI
多$113.1M
$-77.1M
两年增速更快
ANDE
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $329.5M | $540.7M |
| 净利润 | $67.4M | $-15.7M |
| 毛利率 | 70.3% | 37.5% |
| 营业利润率 | 26.6% | 1.0% |
| 净利率 | 20.5% | -2.9% |
| 营收同比 | -2.4% | -14.1% |
| 净利润同比 | 49.6% | 34.0% |
| 每股收益（稀释后） | — | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANDEICUI
| Q4 25 | $329.5M | $540.7M | ||
| Q3 25 | $295.8M | $537.0M | ||
| Q2 25 | $535.0M | $548.9M | ||
| Q1 25 | $370.8M | $604.7M | ||
| Q4 24 | $337.5M | $629.8M | ||
| Q3 24 | $231.9M | $589.1M | ||
| Q2 24 | $492.5M | $596.5M | ||
| Q1 24 | $341.4M | $566.7M |
净利润ANDEICUI
| Q4 25 | $67.4M | $-15.7M | ||
| Q3 25 | $20.1M | $-3.4M | ||
| Q2 25 | $7.9M | $35.3M | ||
| Q1 25 | $284.0K | $-15.5M | ||
| Q4 24 | $45.1M | $-23.8M | ||
| Q3 24 | $27.4M | $-33.0M | ||
| Q2 24 | $36.0M | $-21.4M | ||
| Q1 24 | $5.6M | $-39.5M |
毛利率ANDEICUI
| Q4 25 | 70.3% | 37.5% | ||
| Q3 25 | 57.8% | 37.4% | ||
| Q2 25 | 29.6% | 37.9% | ||
| Q1 25 | 41.2% | 34.7% | ||
| Q4 24 | 63.1% | 36.1% | ||
| Q3 24 | 76.4% | 34.8% | ||
| Q2 24 | 35.6% | 34.8% | ||
| Q1 24 | 37.6% | 32.7% |
营业利润率ANDEICUI
| Q4 25 | 26.6% | 1.0% | ||
| Q3 25 | 8.7% | 2.6% | ||
| Q2 25 | 4.6% | 1.9% | ||
| Q1 25 | 0.9% | 2.1% | ||
| Q4 24 | 19.9% | 6.0% | ||
| Q3 24 | 26.8% | 1.4% | ||
| Q2 24 | 11.6% | 1.3% | ||
| Q1 24 | 4.1% | -1.9% |
净利率ANDEICUI
| Q4 25 | 20.5% | -2.9% | ||
| Q3 25 | 6.8% | -0.6% | ||
| Q2 25 | 1.5% | 6.4% | ||
| Q1 25 | 0.1% | -2.6% | ||
| Q4 24 | 13.4% | -3.8% | ||
| Q3 24 | 11.8% | -5.6% | ||
| Q2 24 | 7.3% | -3.6% | ||
| Q1 24 | 1.6% | -7.0% |
每股收益（稀释后）ANDEICUI
| Q4 25 | — | $-0.63 | ||
| Q3 25 | $0.59 | $-0.14 | ||
| Q2 25 | $0.23 | $1.43 | ||
| Q1 25 | $0.01 | $-0.63 | ||
| Q4 24 | $1.31 | $-0.97 | ||
| Q3 24 | $0.80 | $-1.35 | ||
| Q2 24 | $1.05 | $-0.88 | ||
| Q1 24 | $0.16 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | — |
| 总债务越低越好 | $560.0M | — |
| 股东权益账面价值 | $1.2B | $2.1B |
| 总资产 | $3.7B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资ANDEICUI
| Q4 25 | $98.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $561.8M | $308.6M | ||
| Q3 24 | — | $312.5M | ||
| Q2 24 | — | $302.6M | ||
| Q1 24 | — | $251.4M |
总债务ANDEICUI
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANDEICUI
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.3B | $2.1B |
总资产ANDEICUI
| Q4 25 | $3.7B | $4.1B | ||
| Q3 25 | $3.3B | $4.1B | ||
| Q2 25 | $3.4B | $4.1B | ||
| Q1 25 | $3.8B | $4.2B | ||
| Q4 24 | $4.1B | $4.2B | ||
| Q3 24 | $3.4B | $4.3B | ||
| Q2 24 | $3.3B | $4.3B | ||
| Q1 24 | $3.3B | $4.3B |
负债/权益比ANDEICUI
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-77.1M | $36.0M |
| 自由现金流率自由现金流/营收 | -23.4% | 6.6% |
| 资本支出强度资本支出/营收 | 21.5% | 4.6% |
| 现金转化率经营现金流/净利润 | -0.09× | — |
| 过去12个月自由现金流最近4个季度 | $-56.1M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ANDEICUI
| Q4 25 | $-6.2M | $60.6M | ||
| Q3 25 | $233.9M | $56.7M | ||
| Q2 25 | $299.3M | $11.2M | ||
| Q1 25 | $-350.0M | $51.3M | ||
| Q4 24 | $268.8M | $40.2M | ||
| Q3 24 | $-2.1M | $36.1M | ||
| Q2 24 | $304.4M | $82.0M | ||
| Q1 24 | $-239.6M | $45.8M |
自由现金流ANDEICUI
| Q4 25 | $-77.1M | $36.0M | ||
| Q3 25 | $167.0M | $27.6M | ||
| Q2 25 | $250.5M | $-8.5M | ||
| Q1 25 | $-396.6M | $36.7M | ||
| Q4 24 | $212.9M | $16.1M | ||
| Q3 24 | $-40.0M | $16.2M | ||
| Q2 24 | $275.8M | $62.5M | ||
| Q1 24 | $-266.4M | $29.9M |
自由现金流率ANDEICUI
| Q4 25 | -23.4% | 6.6% | ||
| Q3 25 | 56.5% | 5.1% | ||
| Q2 25 | 46.8% | -1.5% | ||
| Q1 25 | -106.9% | 6.1% | ||
| Q4 24 | 63.1% | 2.6% | ||
| Q3 24 | -17.2% | 2.7% | ||
| Q2 24 | 56.0% | 10.5% | ||
| Q1 24 | -78.0% | 5.3% |
资本支出强度ANDEICUI
| Q4 25 | 21.5% | 4.6% | ||
| Q3 25 | 22.6% | 5.4% | ||
| Q2 25 | 9.1% | 3.6% | ||
| Q1 25 | 12.6% | 2.4% | ||
| Q4 24 | 16.6% | 3.8% | ||
| Q3 24 | 16.3% | 3.4% | ||
| Q2 24 | 5.8% | 3.3% | ||
| Q1 24 | 7.8% | 2.8% |
现金转化率ANDEICUI
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | 0.32× | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
